Schonfeld Strategic Advisors’s CytomX Therapeutics CTMX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-67,732	Closed	-$318K	–	2679
2026 Q1	$318K	Buy	+67,732	New	+$344K	﹤0.01%	1555
2025 Q2	–	Sell	-589,332	Closed	-$375K	–	2121
2025 Q1	$375K	Sell	589,332 -791,468	-57%	-$614K	﹤0.01%	1705
2024 Q4	$1.42M	Buy	1,380,800 +169,000	+14%	+$182K	0.01%	978
2024 Q3	$1.43M	Sell	1,211,800 -163,490	-12%	-$208K	0.01%	1032
2024 Q2	$1.68M	Buy	1,375,290 +100,783	+8%	+$201K	0.01%	982
2024 Q1	$2.78M	Buy	+1,274,507	New	+$2.35M	0.02%	874
2022 Q1	–	Sell	-19,800	Closed	-$85K	–	2646
2021 Q4	$85K	Buy	+19,800	New	+$116K	﹤0.01%	1905

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Schonfeld Strategic Advisors's CTMX Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 67,732 shares — an estimated $318K sold.

Schonfeld Strategic Advisors first reported a position in CTMX in Q4 2021 and held it in 7 quarters. The position peaked at $2.78M in Q1 2024. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Schonfeld Strategic Advisors reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 67,732 CytomX Therapeutics shares in Q2 2026, an estimated $318K.
Schonfeld Strategic Advisors first reported a position in CytomX Therapeutics in Q4 2021 and held it in 7 quarters.
Schonfeld Strategic Advisors's CytomX Therapeutics position peaked at $2.78M in Q1 2024.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.